Overview

• Effective September 1, Eli Lilly will raise the private UK list price of Mounjaro by up to 170%, while a separate agreement shields NHS patients from higher costs.
• Concerned about affordability, private users are stockpiling months of Mounjaro and scouring pharmacies and online providers for pre-hike supplies.
• Novo Nordisk has kept Wegovy and Ozempic prices unchanged, prompting providers to report a 500–600% surge in demand for semaglutide treatments.
• Clinicians warn that abrupt stopping or unsupervised switching can lead to weight regain, metabolic instability and may push patients toward counterfeit jabs on the black market.
• Regulators and NHS England are urging patients to seek professional advice for managed transitions and are reinforcing that NHS supply and eligibility remain unaffected.